News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Dr. Dhruv Khullar Named NAM Emerging Leader in Health and Medicine

hospital interior

Dr. Dhruv Khullar, an associate professor of population health sciences and of medicine at Weill Cornell Medicine, has been selected as an Emerging Leader in Health and Medicine (ELHM) Scholar by the National Academy of Medicine.

The program, which launched in 2016, is designed to increase the organization’s engagement with outstanding interdisciplinary early- to mid-career professionals. NAM selects up to 10 people working in biomedical science, population health, health care, health policy and related fields each year. Scholars participate in leadership training and mentoring and help shape the priorities and work of NAM during their three-year tenures.

Dr. Khullar

Dr. Dhruv Khullar

Oral GLP-1 Medication Helps Patients Maintain Weight Loss

oral vs injectable GLP-1s

Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most—but not all—of their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

While injectable GLP-1s work well for weight loss, keeping the weight off after discontinuing the therapies is challenging. The results of the ATTAIN-MAINTAIN trial, published May 12 in Nature Medicine, showed that switching to the once-daily orforglipron pill may address this need and help maintain the cardiometabolic benefits.

Patients in the phase 3b clinical trial maintained about 75-80% of their weight loss and health benefits, such as reduced waist circumference and improvements in blood pressure, blood sugar, triglycerides and cholesterol levels. Participants also tolerated the oral medication well, with mild to moderate gastrointestinal side effects. The study was sponsored by Eli Lilly and Company, the manufacturer of orforglipron and the injectable GLP-1 tirzepatide. 

Weill Cornell Centers DEI in Community—and Courage

Dr. Heidi Bender, Dr. Linnie Golightly and Fanesse Acquaye

Even as the national conversation around diversity, equity and inclusion is muted, Weill Cornell Medicine continues its work to make sure everyone has a seat at the table.

That was the message relayed on April 23 by Dr. Linnie Golightly, provost and senior associate dean of academic affairs at CUNY School of Medicine. Dr. Golightly was joined by Dr. Heidi Bender, inaugural associate dean for faculty engagement and inclusion, and Fanesse Acquaye, executive director of the Office of Culture, Inclusion & Employee Experience for a fireside chat, as part of the institution’s eighth annual Diversity Week.

The nearly hour-long conversation explored Dr. Golightly’s legacy at Weill Cornell Medicine and her lifelong commitment to building institutions where everyone can feel they belong and every voice is heard. A 1983 graduate of Weill Cornell Medicine, Dr. Golightly spent close to 30 years of her professional career at the institution—joining the faculty in 1997 and then serving as associate dean of diversity and inclusion from 2016 until her departure in 2025.

She also discussed how she’s continuing the work in her current role, noting that the process continues by focusing on the opportunities ahead instead of looking back at the challenges already overcome. She stressed the importance of bridge-building—engaging skeptics and those unfamiliar with this work rather than retreating into like-minded circles.